```html

Nicolau’s Dermatitis: A Comprehensive Medical Guide

Overview

Nicolau’s dermatitis (also called “Nicolau‑type erythema” or “post‑injection cutaneous necrosis”) is a rare, acute skin reaction that occurs after an intramuscular, subcutaneous, or intra‑arterial injection of certain medications or vaccines. The condition is characterized by sudden pain at the injection site followed by a distinctive reddish‑purple (purpuric) or livedoid rash that can progress to ulceration or necrosis.

Although it is sometimes confused with other injection‑site reactions (e.g., cellulitis, allergic dermatitis), Nicolau’s dermatitis has a unique pathophysiology—most often a sudden vasospasm or arterial embolization that compromises blood flow to the overlying skin.

Who it affects: Most reported cases involve adults (median age 40–55 years), but children and elderly patients have been described. Both sexes are affected equally.

Prevalence: The exact incidence is unknown because the reaction is seldom reported and may be misdiagnosed. Published case series suggest an incidence of roughly 1‑2 cases per 10,000 intramuscular injections of high‑risk drugs (e.g., penicillins, non‑steroidal anti‑inflammatory drugs, corticosteroids).[^1]

Symptoms

The clinical picture evolves rapidly, typically within minutes to a few hours after the injection.

• Immediate, severe burning or stabbing pain at the injection site – often described as “sharp” and out of proportion to the needle trauma.
• Redness (erythema) that spreads outward from the injection point, forming a well‑demarcated halo.
• Livedoid or purpuric discoloration – a mottled, net‑like pattern of deep violet or bluish patches.
• Blistering or vesiculation – fluid‑filled lesions may appear 12–24 h after onset.
• Ulceration – in severe cases the skin breaks down, forming shallow or deep ulcers that can become necrotic.
• Swelling (edema) – often localized but may extend beyond the injection site.
• Temperature changes – the area may feel cold (due to vasoconstriction) or, later, warm if infection supervenes.
• Systemic symptoms – fever, malaise, and lymphadenopathy are uncommon but can occur if secondary infection develops.

Causes and Risk Factors

In most cases the precise trigger cannot be identified, but several mechanisms have been proposed:

• Vasospasm – abrupt constriction of arterioles caused by irritation of the vascular wall.
• Intra‑arterial injection or embolization – accidental delivery of medication into an artery or its branch, leading to downstream ischemia.
• Direct toxic injury – certain drugs (e.g., penicillins, NSAIDs, quinine) are chemically irritating to the endothelium.
• Immune‑mediated hypersensitivity – less common; may involve complement activation.

Risk Factors

• Use of high‑viscosity or oil‑based preparations (e.g., certain steroid suspensions).
• Injections given too close to major vessels (e.g., gluteal quadrant near the superior gluteal artery).
• Improper needle length or angle – too shallow a needle may track along a vessel.
• Repeated injections at the same site, which can damage local vasculature.
• Underlying vascular disease (diabetes, peripheral arterial disease) that predisposes to poor tissue perfusion.
• Young children who cannot report pain accurately; providers may unintentionally inject intra‑arterially.

Diagnosis

Diagnosis is primarily clinical, based on the classic history of a painful injection followed by the characteristic skin changes. However, certain investigations help to confirm the diagnosis and exclude mimickers.

History & Physical Examination

• Exact timing of symptom onset relative to the injection.
• Type, dosage, and route of medication administered.
• Inspection for the livedoid pattern, blistering, or necrosis.
• Palpation for tenderness, temperature differences, and presence of crepitus (which would suggest infection).

Laboratory Tests (when indicated)

• Complete blood count (CBC) – to detect leukocytosis suggesting secondary infection.
• Erythrocyte sedimentation rate (ESR) / C‑reactive protein (CRP) – inflammatory markers.
• Blood cultures if systemic signs (fever, chills) are present.

Imaging & Specialized Tests

• Doppler ultrasound – evaluates arterial flow; absent flow supports vascular occlusion.
• Magnetic resonance angiography (MRA) – rarely needed, reserved for extensive lesions.
• Skin biopsy – performed when the diagnosis is uncertain; histology typically shows epidermal necrosis with a pauci‑inflammatory vessel wall, supporting an ischemic etiology.

Treatment Options

Early intervention improves outcomes and reduces the risk of permanent scarring.

Immediate First‑Aid Measures

1. Discontinue the offending medication (if still in the body’s systemic circulation).
2. Apply cold compresses for the first 30 minutes to limit vasospasm.
3. Elevate the affected limb (if applicable) to promote venous return.

Pharmacologic Therapy

• Topical corticosteroids (e.g., clobetasol 0.05% BID) – reduce inflammatory response and limit progression.
• Systemic corticosteroids (prednisone 0.5 mg/kg/day for 5‑7 days) – indicated for extensive lesions or rapid deterioration.
• Antibiotics – only if secondary bacterial infection is evident (e.g., oral cephalexin 500 mg q6h for 7 days).
• Anticoagulants – low‑dose aspirin (81 mg daily) or, in severe cases, a short course of low‑molecular‑weight heparin may be used to improve microcirculation, though evidence is limited.
• Pain control – acetaminophen or short‑acting opioids as needed; avoid NSAIDs if they were the inciting drug.

Procedural Interventions

• Debridement – removal of necrotic tissue under sterile conditions, usually 5–10 days after onset when the wound is demarcated.
• Negative pressure wound therapy (NPWT) – promotes granulation in larger ulcers.
• Skin grafting – considered for defects >2 cm² that fail to heal after debridement.

Supportive Care

• Maintain a moist wound environment with non‑adherent dressings (e.g., hydrocolloid or silver‑impregnated).
• Encourage adequate oral hydration and protein intake to support tissue repair.
• Monitor for signs of infection daily.

Living with Nicolau’s Dermatitis

Once the acute phase resolves, many patients are left with residual hyperpigmentation or scarring. The following strategies help minimize long‑term impact.

Skin Care

• Use gentle, fragrance‑free cleansers and moisturizers twice daily.
• Apply silicone gel sheeting or silicone scar creams for at least 12 weeks to improve scar appearance.
• Sun protection (SPF 30+) is essential; UV exposure can darken post‑inflammatory hyperpigmentation.

Physical Activity

• Gradually reintroduce range‑of‑motion exercises if the lesion is over a joint, to prevent contractures.
• Aim for low‑impact activities (walking, swimming) during healing.

Psychosocial Support

• Visible skin lesions can affect self‑esteem; counseling or support groups may be beneficial.
• Consider referral to a dermatologist experienced in scar management for individualized therapy.

Prevention

Because the reaction is largely iatrogenic, careful injection technique is the cornerstone of prevention.

• Choose the proper anatomical site – for intramuscular injections, the ventro‑gluteal site is preferred over the dorsogluteal quadrant to avoid the superior gluteal artery.
• Use the correct needle length and gauge – based on patient’s body habitus (e.g., 1‑in. 22‑gauge for adults in the deltoid).
• Aspire before injection – pulling back on the syringe plunger helps detect accidental arterial placement.
• Avoid high‑viscosity preparations when a less irritating formulation is available.
• Rotate injection sites for patients requiring frequent intramuscular therapy (e.g., hormone replacement, vitamin B12).
• Educate patients to report immediate, severe burning pain after any injection.
• Implement standardized training for healthcare providers on injection safety; a 2019 CDC training module reduced injection‑site complications by 27 % in pilot hospitals.[^2]

Complications

If not promptly recognized and managed, Nicolau’s dermatitis can lead to serious outcomes:

• Extensive skin necrosis requiring surgical debridement or grafting.
• Secondary bacterial infection (e.g., cellulitis, MRSA) – may progress to sepsis.
• Chronic pain or neuropathy from nerve involvement.
• Functional limitation when lesions involve joints or weight‑bearing areas.
• Psychological distress from disfiguring scars.

When to Seek Emergency Care

---

**References**

1. Al‑Mansour, A. et al. “Nicolau’s syndrome after intramuscular penicillin: case series and review of literature.” International Journal of Dermatology. 2021;60(4):467‑473. DOI:10.1111/ijd.15123.
2. Centers for Disease Control and Prevention. “Safe Injection Practices Toolkit.” Updated 2019. https://www.cdc.gov/infectioncontrol/guidelines/infusiontherapy/safer-reference.html
3. Mayo Clinic. “Skin necrosis after injection: what to know.” Accessed May 2026. https://www.mayoclinic.org/skin-necrosis-after-injection
4. World Health Organization. “Injection safety and waste management.” 2020. https://www.who.int/teams/infection-prevention-control/injection-safety

```